Terms: = Prostate cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Diagnosis
35 results:
1. Transitional zone prostate cancer: Performance of texture-based machine learning and image-based deep learning.
Lee MS; Kim YJ; Moon MH; Kim KG; Park JH; Sung CK; Jeong H; Son H
Medicine (Baltimore); 2023 Sep; 102(39):e35039. PubMed ID: 37773806
[TBL] [Abstract] [Full Text] [Related]
2. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder cancer: United States insurance claims data.
Del Giudice F; Belladelli F; Glover F; Basran S; Li S; Mulloy E; Pradere B; Soria F; Krajewski W; Nair R; Muncey W; Seranio N; Eisenberg ML
World J Urol; 2023 Oct; 41(10):2783-2791. PubMed ID: 37548746
[TBL] [Abstract] [Full Text] [Related]
3. Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: A retrospective observational study.
Okubo Y; Yamamoto Y; Terao H; Suzuki T; Koizumi M; Yoshioka E; Washimi K; Sato S; Yokose T; Kishida T; Miyagi Y
Pathol Res Pract; 2022 Dec; 240():154188. PubMed ID: 36327822
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.
Ge Y; Xu B; Cai H; Jing W; Ouyang Q; Yuan Q; Li X; Fan Y; Shen Y; Shi Q; Wang Q; Cui L; Yin X; Ma G
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2301-2310. PubMed ID: 36198834
[TBL] [Abstract] [Full Text] [Related]
5. Expression Analysis of miRNAs and Their Potential Role as Biomarkers for prostate cancer Detection.
Bergez-Hernández F; Arámbula-Meraz E; Alvarez-Arrazola M; Irigoyen-Arredondo M; Luque-Ortega F; Martínez-Camberos A; Cedano-Prieto D; Contreras-Gutiérrez J; Martínez-Valenzuela C; García-Magallanes N
Am J Mens Health; 2022; 16(5):15579883221120989. PubMed ID: 36082407
[TBL] [Abstract] [Full Text] [Related]
6. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for prostate cancer Treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract] [Full Text] [Related]
8. The impact of the COVID-19 pandemic on the short-term survival of patients with cancer in Northern Portugal.
Morais S; Antunes L; Rodrigues J; Fontes F; Bento MJ; Lunet N
Int J Cancer; 2021 Jul; 149(2):287-296. PubMed ID: 33634852
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
Matulewicz RS; Basak R; Zambrano I; Dearing BA; Schatz D; El Shahawy O; Sherman S; Bjurlin MA
J Urol; 2021 May; 205(5):1444-1451. PubMed ID: 33347778
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of Secondary Sarcomas Among Patients With cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone.
Hird AE; Magee DE; Matta R; Saskin R; Dvorani E; Kulkarni GS; Kodama R; Herschorn S; Narod SA; Nam RK
JAMA Netw Open; 2020 Oct; 3(10):e2013929. PubMed ID: 33006617
[TBL] [Abstract] [Full Text] [Related]
11. Results of the spanish section of the European Randomized Study of Screening for prostate cancer (ERSPC). Update after 21 years of follow-up.
Luján Galán M; Páez Borda Á; Llanes González L; Romero Cajigal I; Berenguer Sánchez A
Actas Urol Esp (Engl Ed); 2020; 44(6):430-436. PubMed ID: 32147352
[TBL] [Abstract] [Full Text] [Related]
12. prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology.
Shan Y; Chen X; Liu K; Zeng M; Zhou J
Abdom Radiol (NY); 2019 Oct; 44(10):3441-3452. PubMed ID: 31144091
[TBL] [Abstract] [Full Text] [Related]
13. Identifying Cases of Metastatic prostate cancer Using Machine Learning on Electronic Health Records.
Seneviratne MG; Banda JM; Brooks JD; Shah NH; Hernandez-Boussard TM
AMIA Annu Symp Proc; 2018; 2018():1498-1504. PubMed ID: 30815195
[TBL] [Abstract] [Full Text] [Related]
14. miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of runx1.
Xu S; Ge J; Zhang Z; Zhou W
Oncol Rep; 2018 Mar; 39(3):1454-1460. PubMed ID: 29328406
[TBL] [Abstract] [Full Text] [Related]
15. A microRNA/runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.
Farina NH; Zingiryan A; Akech JA; Callahan CJ; Lu H; Stein JL; Languino LR; Stein GS; Lian JB
Oncotarget; 2016 Oct; 7(43):70462-70474. PubMed ID: 27634876
[TBL] [Abstract] [Full Text] [Related]
16. Dietary inflammatory index and prostate cancer survival.
Zucchetto A; Gini A; Shivappa N; Hébert JR; Stocco C; Dal Maso L; Birri S; Serraino D; Polesel J
Int J Cancer; 2016 Dec; 139(11):2398-404. PubMed ID: 27242333
[TBL] [Abstract] [Full Text] [Related]
17. Estimation of breast, prostate, and colorectal cancer incidence using a French administrative database (general sample of health insurance beneficiaries).
Doat S; Samson S; Fagot-Campagna A; Tuppin P; Menegaux F
Rev Epidemiol Sante Publique; 2016 Jun; 64(3):145-52. PubMed ID: 27238161
[TBL] [Abstract] [Full Text] [Related]
18. Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome.
Boursi B; Giantonio BJ; Lewis JD; Haynes K; Mamtani R; Yang YX
Eur J Cancer; 2016 May; 59():90-98. PubMed ID: 27017290
[TBL] [Abstract] [Full Text] [Related]
19. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish prostate cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract] [Full Text] [Related]
20. BPH: a tell-tale sign of prostate cancer? Results from the prostate cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract] [Full Text] [Related]
[Next]
